TechMARK movers: Order bookst for AEA
24th Jun 2010 14:11
A 41% increase in orders helped offset the fall in reported profits at AEA Technology. The order book is worth £119.2m and secure sales for the coming year are £59.5m. In the year to March 2010, AEA's revenues were £113.2m. Profit before tax decreased to £3.5m from £7.5m. Stripping out, amortisati
Read moreSkyepharma slides on US Flutiform doubt
24th Jun 2010 13:29
SkyePharma shares fell after the drug developer raised doubts about getting US approval for its asthma drug Flutiform The group said meeting the U.S. Food and Drug Administration's (FDA) requirements for approving Flutiform will require "significant" work. "The company is working with its advisers
Read moreSkyepharma: FDA Flutiform Approval Would Require Extra Work
24th Jun 2010 11:43
LONDON (Dow Jones)--Skyepharma PLC (SKP.LN), a specialist drug delivery company developing oral and inhalation products, said Thursday that the U.S. Food and Drug Administration's requirements for approving Flutiform have changed materially during the course of the development program, and meeting t
Read morePRESS RELEASE: Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
17th Jun 2010 14:00
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer SAN DIEGO, CA -- (MARKETWIRE) -- 06/17/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced t
Read moreTechMARK movers: Kewill receives potential 130p a share offer
14th May 2010 14:44
Kewill is the star performer on TechMARK after it admitted that it has received a bid approach. The 130p a share indicative offer is above the 12 month high hit at the end of 2009. The share price has not hit 130p since 2001. The logistics software supplier says that it made the announcement of
Read moreTechMARK movers: Ark shares recover
10th Mar 2010 16:34
ARK Therapeutics has made back some of yesterday's loss after the publication of its 2009 figures. The drug developer reported an increase in its loss from £17.6m to £21.2m. Ark still has net cash of £20.7m and this should last until the second half of 2011. Ark says that it has decided to put t
Read moreTechMARK movers: Skyepharma hit by FDA drug refusal
22nd Jan 2010 14:42
Skyepharma shares continue to decline following yesterday afternoon's announcement that the FDA will not approve the application for Flutiform as a treatment for asthma in patients at least 12 years old. The FDA said that there are a "number of substantive issues to be addressed, which, if underta
Read moreRound-up: Capital & Regional, International Ferro, Synergy Healthcare...
12th Nov 2009 14:11
Property fund manager Capital & Regional reports valuations in the UK fund businesses, particularly in retail warehouses, are trending higher in the fourth quarter. This reflects the strength of the investment market which is likely for the balance of this year to outweigh pressure on income. C&R
Read moreTechMARK movers: Skyepharma gets Flutiform boost
2nd Nov 2009 15:25
Pharma company Skyepharma says that its marketing partner Mundipharma International Corporation has completed the Phase III clinical study for the European development of Flutiform for treating asthma. The higher dose strength study "met its primary endpoints". Flutiform is a fixed-dose combinatio
Read moreLondon close: Footsie plunges after Wall Street reversal
1st Sep 2009 16:43
A sharp reversal in US stocks' fortunes ensured Footsie finished deep in the red after abruptly giving up an attempt to climb into positive territory. Miners were weak on lower metals prices, with Kazakh pair ENRC and Kazakhmys among the worst hit. Lower metals prices also hurt the likes of Antof
Read moreLondon afternoon: Footsie still stuck after plunge
1st Sep 2009 14:41
There has been little change in the FTSE 100 since it abruptly took a downward turn this morning Kazakh resources group ENRC is leading the mining sector lower, closely followed by fellow Kazakh operation Kazakhmys. Lower metals prices are also hitting the likes of Antofagasta, Anglo American, Lon
Read moreTechMARK movers: Skyepharma down on US delay
1st Sep 2009 13:04
Skyepharma is leading the fallers on news that the US launch of the drug developer's asthma treatment Flutiform will be delayed for two years at least after the US Food and Drug Administration insisted on more data on dosing. The result is a blow for Skyepharma, which originally had expected appro
Read moreLondon midday: Banks and miners lead retreat
1st Sep 2009 12:16
Banks and miners are dragging the market lower and have pushed the Footsie below the 4,900 level. Kazakh resources group ENRC is leading the mining sector lower, closely followed by fellow Kazakhi operation Kazakhmys. Lower metals prices are also hitting the likes of Antofagasta, Anglo American, L
Read moreSector movers: Drugs progress boosts Pharma stock
1st Sep 2009 11:12
Positive updates from two big hitters have given the pharmaceuticals sector a shot in the arm. AstraZeneca is one of the FTSE 100's best performers after announcing it is to press ahead with plans to submit its ticagrelor drug, Brilinta, for regulatory approval in the fourth quarter of 2009 after
Read moreLondon open: Quiet start for Footsie
1st Sep 2009 08:54
It has been a very quiet start to the post-bank holiday weekend with news at a premium and what has come out largely small cap focused. Asia-focused bank Standard Chartered has agreed to sell its entire 14.85% stake in BC Card to Korean private equity firm Vogo Fund and its affiliates for an undis
Read more